In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.
A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.
New research from Roswell Park Comprehensive Cancer Center reports that timing of radiation treatments can significantly reduce severity of mucositis and its related impacts.
Final results from the first U.S. clinical study of CIMAvax-EGF show that this Cuban immunotherapy is safe and showed promising efficacy as part of a treatment combination with nivolumab in patients with advanced non-small cell lung cancer.
Several Roswell Park Comprehensive Cancer Center experts were invited to highlight research and best practices during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.
Roswell Park Comprehensive Cancer Center has been recognized as one of America’s Best Employers for Diversity 2019. The Buffalo cancer center was ranked 67th among 500 employers and 8th among the 30 employers within the health care sector to be named to the list, which is based on employee surveys.
The largest study to date to compare exposure to toxicants among users of electronic cigarettes, smokers and nonsmokers has been completed, suggesting possible benefits for smokers who switch completely to electronic cigarettes
New research out of Roswell Park Comprehensive Cancer Center shows that cancer patients who exercise regularly both before and after their diagnosis are significantly more likely to survive than those who are sedentary, adding to the growing body of evidence that physical activity is an important part of a cancer prevention and treatment strategy. The results were published in a recent issue of the journal Cancer Causes & Control.
Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. A two-year study by a multidisciplinary team of surgeons and other cancer specialists shows that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications or patient requests for additional
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.
In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.
A new derivative of a compound found in the bark of a rare Chinese tree has powerful anticancer properties and a low toxicity profile, according to new research from a Roswell Park Comprehensive Cancer Center published in the Journal of Experimental & Clinical Cancer Research.
Governor Andrew M. Cuomo today announced Buffalo-based Roswell Park Comprehensive Cancer Center has formed the Innovative Immunotherapy Alliance S.A., the first-ever biotech venture between the U.S. and Cuba.
Through a grant award provided by the Cancer MoonshotSM, Roswell Park Comprehensive Cancer Center will support and advance some of the nation’s most ambitious cancer research projects.
The expertise of two regional research teams has earned a federal grant of nearly $20 million to create the nation’s first program dedicated to the study of flavored tobacco.
A team led by Marc Ernstoff, MD, of Roswell Park Comprehensive Cancer Center found that a drug complex containing IL-15 is both safe and well tolerated in patients with advanced solid tumors.
A new Roswell Park/Stony Brook Children's Hospital study reports striking findings: that young users of newer “pod” e-cigarette devices are absorbing nicotine at levels approaching nicotine exposure from traditional combustible cigarettes.
A Roswell Park-led research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target. Their findings were published in the journal Nature Communications.
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine — before surgery — whether the tumor is benign or malignant.
y-two local high school students participated in a unique career development program at Roswell Park Comprehensive Cancer Center this summer. The Buffalo Healthcare Exploration (BHE) program